Apel Daniel Joseph
Chief Financial Officer
Apel Daniel Joseph has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Apr 24, 2026.
On the most recent filing, Apel Daniel Joseph is listed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC. Inside the rolling window, Apel Daniel Joseph reported no open-market purchases and 1 open-market sale totaling $934K in ARWR.
Companies traded
Other insiders at ARWR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$934K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Apel Daniel Joseph made?
Apel Daniel Joseph has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Apel Daniel Joseph trade?
Apel Daniel Joseph has filed SEC Form 4 disclosures for 1 company, including ARWR.
When was Apel Daniel Joseph's most recent SEC Form 4 filing?
Apel Daniel Joseph's most recent SEC Form 4 filing on Tracefour is dated Apr 24, 2026.
What is Apel Daniel Joseph's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Apel Daniel Joseph is listed as Chief Financial Officer.
What is Apel Daniel Joseph's total buy and sell value in the current window?
Inside the rolling retention window, Apel Daniel Joseph bought $0 and sold $934K based on SEC Form 4 filings.
What was Apel Daniel Joseph's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,095 ARWR shares on 2026-04-22, worth $934K, per SEC Form 4 filings.